Lord, Abbett & Co. LLC Clovis Oncology, Inc. Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $9.68 Million - $13.1 Million	-193,117 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $5.28 Million - $7.73 Million	-91,448 Reduced 32.14%	193,117 $13.1 Million
Q3 2017 Nov 14, 2017	SELL	$67.17 - $84.81 $19.8 Million - $25 Million	-294,832 Reduced 50.89%	284,565 $23.4 Million
Q2 2017 Aug 14, 2017	BUY	N/A	579,397	579,397 $54.2 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.